Titles
- Increases in reimbursement for brand-name drugs in Part D1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Key design components and considerations for establishing a single-payer health care system: testimony before the Committee on the Budget, United States House of Representatives1
- Let the sunshine in: assuring public involvement in state Medicaid policy making1
- Medicaid and CHIP eligibility, enrollment, and cost sharing policies as of January 2020: findings from a 50-state survey1
- Medicaid and personal responsibility waivers: opportunities and challenges in evaluating potential impacts1
- Medicaid changes in Better Care Reconciliation Act (BCRA) go beyond ACA repeal and replace1
- Medicaid copayments1
- Medicaid premium assistance programs: what information is available about benefit and cost-sharing wrap-around coverage?1
- Medicaid waivers and budget neutrality: the basics1
- Medicaid: what we learned from the recent debate and what to watch for in September 20171
- Medicare Advantage 2017 spotlight: enrollment market update1
- Medicare Advantage benefit design: what does it provide, what doesn't it provide, and should standards apply?1
- Medicare Part D's medication therapy management: shifting from neutral to drive1
- Medicare Part D: a first look at prescription drug plans in 20191
- Medicare beneficiaries' out-of-pocket spending for health care1
- Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality1
- Medicare's new adventure: the Part D drug benefit1
- Medicare: 50 years of ensuring coverage and care1
- Navigating antitrust concerns in multi-payer initiatives1